

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

InVivoMab anti-human CD3

RRID:AB_1107632

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0001-2, RRID:AB_1107632)

Antibody Information

URL: http://antibodyregistry.org/AB_1107632

Proper Citation: (Bio X Cell Cat# BE0001-2, RRID:AB_1107632)

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vitro Organoids/Organ-on-Chip

Antibody Name: InVivoMab anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: clone OKT-3

Antibody ID: AB_1107632

Vendor: Bio X Cell

Catalog Number: BE0001-2

Alternative Catalog Numbers: BE0001-2-50MG, BE0001-2-100MG, BE0001-2-1MG, BE0001-2-25MG, BE0001-2-5MG

Record Creation Time: 20260114T193410+0000

Record Last Update: 20260706T190415+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-human CD3.

No alerts have been found for InVivoMab anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. *Cancer research*, 85(4), 692.

Rahman J, et al. (2025) A CD4+ T cell-intrinsic complement C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 cell contraction. *Immunity*, 58(6), 1438.

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. *bioRxiv : the preprint server for biology*.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Chen C, et al. (2024) Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. *Cell reports. Medicine*, 5(8), 101686.

Du X, et al. (2024) Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis. *The Journal of clinical endocrinology and metabolism*, 109(11), 2823.

Lim YJ, et al. (2024) MicroRNA-19b exacerbates systemic sclerosis through promoting Th9 cells. *Cell reports*, 43(8), 114565.

Scott KA, et al. (2024) Covalent targeting of splicing in T cells. *Cell chemical biology*.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. *Immunity*, 56(9), 2036.

Zwijnenburg AJ, et al. (2023) Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. *Immunity*, 56(8), 1955.

Hadley P, et al. (2023) Precise surface functionalization of PLGA particles for human T cell modulation. *Nature protocols*, 18(11), 3289.

Pei S, et al. (2023) A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. *Cancer discovery*, 13(9), 2032.

Gbyli R, et al. (2022) In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. *Leukemia*, 36(5), 1313.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.

Rossignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. *iScience*, 25(6), 104353.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell reports. Medicine*, 3(9), 100744.

Mian SA, et al. (2021) Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. *Blood cancer discovery*, 2(2), 135.

Matias MI, et al. (2021) Regulatory T cell differentiation is controlled by ?KG-induced alterations in mitochondrial metabolism and lipid homeostasis. *Cell reports*, 37(5), 109911.

Guo X, et al. (2021) Effective chimeric antigen receptor T cells against SARS-CoV-2. *iScience*, 24(11), 103295.

O'Connor RA, et al. (2021) T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. *Oncoimmunology*, 10(1), 1940675.